Saidete Biopharmaceutical

Saidete Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages its proprietary antibody engineering platforms to develop a diverse pipeline of monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Its lead programs target high-value oncology markers such as Claudin 18.2 and immune checkpoints like PD-1 and CTLA-4. Saidete aims to address unmet medical needs in solid tumors, particularly gastric and pancreatic cancers, through precision medicine and advanced biologics.